• 1
    Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:251929.
  • 2
    Gadducci A, Cosio S, Conte PF, Genazzani AR. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 2005;55:15366.
  • 3
    Ten Bokkel HW, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:218393.
  • 4
    Gore M, Ten Bokkel HW, Carmichael J et al. Clinical evidence for topotecan-paclitaxel non–cross-resistance in ovarian cancer. J Clin Oncol 2001;19:1893900.
  • 5
    Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:331222.
  • 6
    De Placido S, Scambia G, Di Vagno G et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: multicenter Italian trials in ovarian cancer (MITO-1) randomized study. J Clin Oncol 2004;22:263542.
  • 7
    Pfisterer J, Weber B, Du Bois A et al. Paclitaxel/carboplatin vs. paclitaxel/carboplatin followed by topotecan in first-line treatment of advanced ovarian cancer. Mature results of a gynecologic cancer intergroup phase III trial of the AGO OVAR and GINECO [abstract]. ASCO 2005;23:456 Abstracts 2005.
  • 8
    Hoskins P, Eisenhauer E, Beare S et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 1998;16:22337.
  • 9
    Homesley HD, Hall DJ, Martin DA et al. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 2001;83:3949.
  • 10
    Clarke-Pearson DL, Van Le L, Iveson T et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J Clin Oncol 2001;19:396775.
  • 11
    Gore M, Oza A, Rustin G et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer 2002;38:5763.
  • 12
    Creemers GJ, Gerrits CJ, Eckardt JR et al. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 1997;15:108793.
  • 13
    Jelliffe RW. Letter: creatinine clearance: bedside estimate. Ann Intern Med 1973;79:6045.
  • 14
    Gerrits CJ, Burris H, Schellens JH et al. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors. Clin Cancer Res 1998;4:11538.
  • 15
    Rothenberg ML, Liu PY, Wilczynski S et al. Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326). Gynecol Oncol 2001;82:31722.
  • 16
    Bolis G, Danese S, Tateo S et al. Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 2006;16(Suppl. 1):748.
  • 17
    Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:24605.
  • 18
    Markman M, PL, Wilczynski S, Monk B, Copeland L, Alberts D. Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I 2006;24(Suppl.):2575.